AIM ImmunoTech, Inc. (AIM)
| Market Cap | 27.96M |
| Revenue (ttm) | 146,000 |
| Net Income (ttm) | -18.34M |
| Shares Out | 48.05M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,682 |
| Open | 0.590 |
| Previous Close | 0.591 |
| Day's Range | 0.580 - 0.637 |
| 52-Week Range | 0.550 - 2.000 |
| Beta | -0.44 |
| Analysts | Buy |
| Price Target | 5.69 (+877.7%) |
| Earnings Date | Nov 9, 2022 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomy... [Read more...]
Financial Performance
In 2021, AIM ImmunoTech's revenue was $135,000, a decrease of -17.18% compared to the previous year's $163,000. Losses were -$19.13 million, 32.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AIM stock is "Buy." The 12-month stock price forecast is 5.69, which is an increase of 877.66% from the latest price.
News
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Int...
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
OCALA, Fla.--(BUSINESS WIRE)--The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced that the Company has filed its Definitive Proxy State...
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tre...
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tre...
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evalua...
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
Company receives IRB approval of study protocol
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types ...
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment ...
Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions G...
AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study
AIM ImmunoTech Inc (NYSE: AIM) reported follow-on data from its published single-center named patient program. For the study, patients with locally advanced pancreatic cancer (LAPC) or metastatic disea...
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as mainte...
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Secur...
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25...
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation's leading business incubators dedicated to life sciences and biotechnolo...
AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent...
Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the Netherlands Further exp...
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued...
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact' on...
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat...
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancre...
- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endpoint ...
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulat...
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046)
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastati...
Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint
AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tre...
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and ...
OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tre...